Michelle Kupka is a partner with Baker Tilly US, LLP. As a partner at Baker Tilly, Michelle leverages more than 28 years of public accounting and advisory experience to support the assurance, risk management and consulting needs of various companies in the life science and technology industries.
Leading the New England office’s life sciences practice, Michelle advises companies in the biotechnology, pharmaceutical and medical device industries, helping them to navigate the unique and continually evolving challenges that impact life sciences companies at varying stages of development – from small, pre-revenue organizations to billion-dollar multinational enterprises.
Her extensive experience includes dexterity across the assurance spectrum – financial statement audits, reviews, System and Organization Controls (SOC) audits and other attestation engagements – and she is also well-versed in the nuances of regulatory compliance, transactions and due diligence, and pre- and post-IPO advisory services. Her advisory experience with both publicly traded and privately held companies also extends to highly technical areas such as stock-based compensation arrangements, complex revenue transactions, purchase accounting and business combinations.
Michelle spent nearly 20 years with a Boston based business consulting and financial advisory firm before its combination with Baker Tilly in December 2021, working closely with life sciences and technology companies to address their evolving assurance and consulting needs. Prior to that, Michelle spent nine years with a Chicago based accounting firm, in their Boston high technology practice.